Literature DB >> 32434708

SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.

Johannes Korth1, Benjamin Wilde2, Sebastian Dolff3, Olympia E Anastasiou4, Adalbert Krawczyk3, Michael Jahn2, Sebastian Cordes5, Birgit Ross6, Stefan Esser7, Monika Lindemann8, Andreas Kribben2, Ulf Dittmer4, Oliver Witzke3, Anke Herrmann4.   

Abstract

BACKGROUND: The novel coronavirus SARS-CoV-2 is associated with a severe respiratory manifestation, COVID-19, and presents a challenge for healthcare systems worldwide. Healthcare workers are a vulnerable cohort for SARS-CoV-2 infection due to frequent and close contact to patients with COVID-19. STUDY
DESIGN: Serum samples from 316 healthcare workers of the University Hospital Essen, Germany were tested for SARS-CoV-2-IgG antibodies. A questionnaire was used to collect demographic and clinical data. Healthcare workers were grouped depending on the frequency of contact to COVID-19 patients in high-risk-group (n = 244) with daily contact to known or suspected SARS-CoV-2 positive patients, intermediated-risk-group (n = 37) with daily contact to patients without known or suspected SARS-CoV-2 infection at admission and low-risk-group (n = 35) without patient contact.
RESULTS: In 5 of 316 (1.6 %) healthcare workers SARS-CoV-2-IgG antibodies could be detected. The seroprevalence was higher in the intermediate-risk-group vs. high-risk-group (2/37 (5.4 %) vs. 3/244 (1.2 %), p = 0.13). Four of the five subject were tested negative for SARS-CoV-2 via PCR. One (20 %) subject was not tested via PCR since he was asymptomatic.
CONCLUSION: The overall seroprevalence of SARS-CoV-2 in healthcare workers of a tertiary hospital in Germany is low (1.6 %). The data indicate that the local hygiene standard might be effective.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody detection; COVID-19; Healthcare workers; SARS-CoV-2; Seroprevalence

Mesh:

Substances:

Year:  2020        PMID: 32434708      PMCID: PMC7219425          DOI: 10.1016/j.jcv.2020.104437

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


Background

In 2019, a novel coronavirus was identified. It first appeared in Wuhan, China and caused a cluster of pneumonia cases. The virus was named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The World Health Organization designated the disease COVID-19 (coronavirus disease 2019) [1]. It caused a pandemic, and lead to a challenge for healthcare systems. The number of confirmed cases worldwide increased to 3.3 million and the German public health institute (Robert Koch institute) reported 161,703 cases and 6575 deaths on May 2, 2020 in Germany. In response to the disease spreading, German hospitals started to create capacities by canceling elective admissions. The University Hospital of Essen was designated as hospital of admission for COVID-19 patients for an area of around 5 million residents. The main route of transmission is person-to-person spread [2]. A vulnerable cohort for infection due to frequent and close contact to COVID-19 patients are healthcare workers [3,4]. To avoid patient-to-staff transmission adherence to strict hygiene standards is important [5] The infection with the SARS-CoV-2 usually leads to seroconversion 11–14 days after the first symptoms [6]. However, due to asymptomatic and oligosymptomatic infections [7,8] testing only symptomatic individuals can lead to a significant underestimation of the SARS-CoV-2 seroprevalence.

Objectives

The study presents the results of the first SARS-CoV-2 seroprevalence study in 316 healthcare workers of the University Hospital Essen, Germany. In addition, this study evaluates the local hygiene standards by the rate of infections on the designated COVID-19 units after admission of the first COVID-19 patient at the beginning of March.

Study design

Health care workers of the University Hospital Essen were recruited in this prospective cross-sectional monocentric study. Participants were grouped depending on the frequency of contact to COVID-19 patients: (i) High-risk group with daily contact to COVID-19 patients on the designated wards and on the intensive care units, (ii) intermediated-risk group with daily non−COVID-19 patient contact and as a control (iii) low-risk group without daily patient contact. For staff members of the high-risk group on designated COVID-19 wards a local hygiene standard was prepared (Fig. 1 ). Staff on wards without known or suspected COVID-19 patients (intermediate-risk group) adhere to basic hygiene standards according to the WHO. In addition, all staff members have to wear surgical mask since April 14th. The period of sampling was from March 25th, 2020 until April 21th, 2020. Anti-SARS-CoV-2-IgG antibodies were detected in sera using an semi-quantitative enzyme-linked immunosorbent assay (ELISA) (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany) according to the manufacturer’s instructions.
Fig. 1

Essentials of the hygiene standard for COVID-19 of the University Hospital Essen.

Essentials of the hygiene standard for COVID-19 of the University Hospital Essen. Fisher’s exact test was used as applicable. Informed consent was obtained from all participants. This study has been approved by the ethics committee of the medical faculty of the University Duisburg- Essen (20−9208-BO).

Results

Overall, 317 employees participated in the study. Since one subject was diagnosed for SARS-CoV-2 infection via PCR after a vacation in March 2020 and the comparison between groups was focused on unknown infection of healthcare workers, the subject (intermediate-risk group) was excluded from further analyzes. Subjects characteristics are listed in Table 1 . SARS-CoV-2-IgG antibodies were detected in 5 of 316 (1.6 %) subjects. Out of these, 3 of 244 (1.2 %) subjects belonging to the high-risk group and in 2 of 37 (5.4 %) belonging to the intermediate-risk group. The seroprevalence was higher in the intermediate-risk vs. high-risk group with an odds ratio of 0.22 (confidence interval 95 % 0.04–1.35; p = 0.13). No participant of the control group tested positive for SARS-CoV-2-IgG antibodies. The mean S/CO-value was 2.7 +/- 1.4 and did not differ significantly between groups (Table 1). Four of the five subjects (80 %) with detectable antibodies reported COVID-19 associated symptoms in the past 3 months including headache (40 %) and sneezing (40 %). General malaise, anosmia and fever were observed in just one case each. None of the subjects suffered from cough, sore throat or dyspnea. One of the five subjects (20 %) had no symptoms at all. None of the subjects were hospitalized. The transmission route could not be elucidated in all cases: Three subjects had suspected infection after unprotected professional COVID-19 exposure and in two cases the route of infection is unknown. PCR of a nasopharyngeal swab was performed in 4 out of the 5 cases without SARS-CoV-2 RNA detection.
Table 1

subject characteristics, SD standard deviation, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, IgG immunoglobulin G, S/co signal-to-cut-off ratio.

high-risk
intermediate-risk
low-risk
overall
n%n%n%n%
24477%3712%3511%316100 %
female15764%2157%2674%20465%
age (+/- SD)36.7 (+/- 10.7)42.3 (+/- 13.2)
profession
nurse17873 %2773 %26%20766%
physician5924%1027%926 %7825%
lab assistant00%00%2057%206%
other73%00%411%113%
SARS-CoV-2 IgG positive31,2%25,4%00%51,6%
SARS-CoV-2 IgG S/co (+/- SD)3.0 (+/- 1.8)2.2 (+/- 1.1)02.7 (+/- 1.4)



symptomatic SARS-CoV-2 infection
sneeze020240 %
headache110240 %
anosmia010120 %
muscle ache100120 %
general malaise100120 %
diarrhoea010120 %
fever100120 %
cough00000%
shortness of breath00000%
sore throat00000%
asymptomatic100120 %
subject characteristics, SD standard deviation, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, IgG immunoglobulin G, S/co signal-to-cut-off ratio.

Discussion

The aim of this study was to determine the SARS-CoV-2 seroprevalence in healthcare workers of the University Hospital Essen, Germany. In 5 of 316 (1.6 %) healthcare workers antibodies could be detected. The seroprevalence was lower in the high-risk group vs. intermediate-risk group (3/244 (1.2 %) vs. 2/37 (5.4 %), with an odds ratio of 0.22 (confidence interval 95 % 0.04–1.35; p = 0.13). No participant of the low-risk group tested positive for SARS-CoV-2-IgG antibodies. These findings reveal the overall seroprevalence is low, which corresponds to another study from the Santa Clara County, United States with approximately 3500 subjects and a seroprevalence of 1.5 % [9]. Other studies observe higher infection rates in healthcare workers. In a study of 957 employees in another German tertiary hospital 52 (5.4 %) employees tested positive for SARS-CoV-2 PCR. The authors underline the vulnerability of healthcare workers in the ongoing pandemic. Similar findings were observed in a Dutch study of 1353 healthcare workers of whom 86 (6%) were tested positive for SARS-CoV-2 via nasal swab [10]. Interestingly the authors suppose the infection to be community acquired during the early phase of pandemic. An even higher rate of infection of healthcare workers was observed in a study from the United Kingdom by Keeley et al., where 1533 symptomatic healthcare workers were tested for SARS-CoV-2 infection via PCR of whom 282 (18 %) were tested positive [11]. They conclude that early identification of symptomatic staff members is crucial to avoid virus transmission due to staff members and to maximize the available workforce. However, comparison to the current study is restricted since the other studies used nasal swab and PCR to determine the rate of infection, although the nasal swab has a volatile positive rate which depends on the practical application and the onset of infection [12] and the PCR has to be improved [13]. An important approach to prevent patient-to-staff infection is the adherence to hygiene guidelines. The low seroprevalence in the high-risk group might be an indicator that the local hygiene standard is effective (Fig. 1). However, the higher seroprevalence in the intermediate-group suggests that the awareness of COVID-19 patient-to staff transmission must be maintained, even in non−COVID-19 wards. Yet the current study did not evaluate the adherence to local guidelines. To estimate the efficiency of the hygiene standard determination of SARS-CoV-2 seroprevalence might be performed. Furthermore it can provide an overview of the current seroprevalence of the population in the context of missing vaccination and in the context development of herd immunity [14]. Healthcare workers with immunity against SARS-CoV-2 may be less vulnerable for SARS-CoV-2 infection. However antibody detection is no assurance of protective immunity [15]. An interesting finding of the current study underlines the limitation of the nasal swab diagnostic since in four subject the PCR diagnostic was negative though antibody detection was positive. In addition one subject with SARS-CoV-2 antibody detection was asymptomatic. Asymptomatic infections could be observed in other studies in up to 50 % of cases [16,17]. This is another important aspect for the adherence to hygiene standards since asymptomatic infection provide a route of community acquired SARS-CoV-2 infection into hospital care. In conclusion the seroprevalence of healthcare workers of a tertiary hospital in Germany was 1.6 %. The local hygiene standard might be effective to provide patient-to-staff transmission at the COVID-19 wards. Awareness for COVID-19 infections is crucial even in non−COVID-19 wards.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

Andreas Kribben has received grants for clinical studies, speaker’s fee, honoraria and travel expenses from Actelion, Amgen, Amicus, Alexion, Astellas, Bayer, Baxter, Binding Site, Bristol Myers, Chiesi, CytoSorbents, Fresenius, GlaxoSmithKline, Hexal, Janssen, Kyowa Kirin, MSD, Novartis, Otsuka, Peripal, Pfizer, Roche, Sanofi, Shire, Teva, and Vifor Fresenius Medical. Oliver Witzke has received research grants for clinical studies, speaker’s fees, honoraria and travel expenses from Amgen, Alexion, Astellas, Basilea, Biotest, Bristol-Myers Squibb, Correvio, Chiesi, Gilead, Hexal, Janssen, Dr. F. Köhler Chemie, MSD, Novartis, Roche, Pfizer, Sanofi, TEVA and UCB. Johannes Korth has received grants speaker's fee, honoraria and travel expenses from Astellas, Basilea, Chiesi, Janssen, Novartis and Roche. The other authors declared no conflict of interests.

Author contributions

Johannes Korth: Project administration, Conceptualization, Methodology, Investigation, Writing - Original Draft; Anke Herrmann: Project administration, Investigation, Conceptualization, Methodology, Investigation, Writing - Original Draft; Benjamin, Wilde: Conceptualization, Methodology, Investigation, Writing - Original Draft; Sebastian Dolff: Methodology, Writing - Original Draft; Olympia E. Anastasiou: Conceptualization, Methodology, Writing - Original Draft, Validation; Adalbert Krawczyk: Methodology, Investigation, Validation; Michael Jahn: Resources, Investigation, Writing - Original Draft; Sebastian Cordes: Resources, Investigation, Writing - Original Draft; Birgit Ross: : Methodology, Investigation; Stefan Esser: : Methodology, Investigation, Resources; Monika Lindemann: Methodology, Investigation, Resources; Andreas Kribben: Conceptualization, Methodology, Writing - Original Draft; Ulf Dittmer: Conceptualization, Methodology, Writing - Original Draft, Investigation; Oliver Witzke: Conceptualization, Methodology, Investigation, Writing - Original Draft; All authors approved the final manuscript.
  14 in total

1.  COVID-19 and Risks Posed to Personnel During Endotracheal Intubation.

Authors:  David N Weissman; Marie A de Perio; Lewis J Radonovich
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

2.  Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong.

Authors:  S C Y Wong; R T-S Kwong; T C Wu; J W M Chan; M Y Chu; S Y Lee; H Y Wong; D C Lung
Journal:  J Hosp Infect       Date:  2020-04-04       Impact factor: 3.926

3.  Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.

Authors:  Ranawaka Apm Perera; Chris Kp Mok; Owen Ty Tsang; Huibin Lv; Ronald Lw Ko; Nicholas C Wu; Meng Yuan; Wai Shing Leung; Jacky Mc Chan; Thomas Sh Chik; Chris Yc Choi; Kathy Leung; Kin Ho Chan; Karl Ck Chan; Ka-Chi Li; Joseph T Wu; Ian A Wilson; Arnold S Monto; Leo Lm Poon; Malik Peiris
Journal:  Euro Surveill       Date:  2020-04

4.  Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China.

Authors:  Yi Luo; Edwin Trevathan; Zhengmin Qian; Yirong Li; Jin Li; Wei Xiao; Ning Tu; Zhikun Zeng; Pingzheng Mo; Yong Xiong; Guangming Ye
Journal:  Emerg Infect Dis       Date:  2020-04-24       Impact factor: 6.883

5.  Developing antibody tests for SARS-CoV-2.

Authors:  Anna Petherick
Journal:  Lancet       Date:  2020-04-04       Impact factor: 79.321

6.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

7.  Clinical Features and Outcomes of Asymptomatic Cases of SARS-CoV-2 Infection.

Authors:  Jianguo Wu; Jun Liang; Hongji Zhou; Fengying Peng; Bin Wang; Wei Jiang; Bei Jia; Tao Luo
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

8.  Asymptomatic cases in a family cluster with SARS-CoV-2 infection.

Authors:  Xingfei Pan; Dexiong Chen; Yong Xia; Xinwei Wu; Tangsheng Li; Xueting Ou; Liyang Zhou; Jing Liu
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

9.  Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.

Authors:  Kin On Kwok; Florence Lai; Wan In Wei; Samuel Yeung Shan Wong; Julian W T Tang
Journal:  J Infect       Date:  2020-03-21       Impact factor: 6.072

10.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Authors:  Sebastian Hoehl; Holger Rabenau; Annemarie Berger; Marhild Kortenbusch; Jindrich Cinatl; Denisa Bojkova; Pia Behrens; Boris Böddinghaus; Udo Götsch; Frank Naujoks; Peter Neumann; Joscha Schork; Petra Tiarks-Jungk; Antoni Walczok; Markus Eickmann; Maria J G T Vehreschild; Gerrit Kann; Timo Wolf; René Gottschalk; Sandra Ciesek
Journal:  N Engl J Med       Date:  2020-02-18       Impact factor: 91.245

View more
  127 in total

1.  Seroprevalence to SARS-CoV-2 Among Healthcare Workers in an Exclusive Pediatric Hospital.

Authors:  Manoj Madhusudan; Janani Sankar; K Dhanalakshmi; Sullochana Putlibai; S Balasubramanian
Journal:  Indian Pediatr       Date:  2021-03-15       Impact factor: 1.411

2.  Screening for SARS-CoV-2 via PCR and serological testing in asymptomatic healthcare workers.

Authors:  Taimur Safder; Peter A McCullough; Kevin R Wheelan; Gelareh Rahimi; Sandra Zurawski; Gerard Zurawski; Jinghua Gu; Xuan Wang; Uthra Balaji; Mezgebe Berhe; Laura Clariday; Rebecca Baker; Kristen Chionh; Giselle Carino; Uriel S Sandkovsky
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-30

3.  Seroprevalence of SARS-CoV-2 Antibody in Echocardiography and Stress Laboratory.

Authors:  Renuka Jain; Stacie Kroboth; Denise Ignatowski; Bijoy K Khandheria
Journal:  J Patient Cent Res Rev       Date:  2021-04-19

4.  SARS-CoV-2 Seroprevalence Among Healthcare Workers by Job Function and Work Location in a New York Inner-City Hospital.

Authors:  Murli U Purswani; Jessica Bucciarelli; Jose Tiburcio; Shamuel M Yagudayev; Georgia H Connell; Arafat A Omidiran; Launcelot Hannaway; Cosmina Zeana; Maureen Healy; Gary Yu; Doug Reich
Journal:  J Hosp Med       Date:  2021-05       Impact factor: 2.960

5.  Specific exposure of ICU staff to SARS-CoV-2 seropositivity: a wide seroprevalence study in a French city-center hospital.

Authors:  Emmanuel Vivier; Caroline Pariset; Stephane Rio; Sophie Armand; Fanny Doroszewski; Delphine Richard; Marc Chardon; Georges Romero; Pierre Metral; Matthieu Pecquet; Adrien Didelot
Journal:  Ann Intensive Care       Date:  2021-05-13       Impact factor: 6.925

6.  SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study.

Authors:  Johannes Korth; Benjamin Wilde; Sebastian Dolff; Jasmin Frisch; Michael Jahn; Adalbert Krawczyk; Mirko Trilling; Leonie Schipper; Sebastian Cordes; Birgit Ross; Monika Lindemann; Andreas Kribben; Ulf Dittmer; Oliver Witzke; Anke Herrmann; Olympia Evdoxia Anastasiou
Journal:  Int J Environ Res Public Health       Date:  2021-04-25       Impact factor: 3.390

7.  Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates.

Authors:  Rupam Bhattacharyya; Ritoban Kundu; Ritwik Bhaduri; Debashree Ray; Lauren J Beesley; Maxwell Salvatore; Bhramar Mukherjee
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

8.  COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study.

Authors:  Anke Hildebrandt; Oktay Hökelekli; Lutz Uflacker; Henrik Rudolf; Sören G Gatermann
Journal:  Int J Hyg Environ Health       Date:  2021-05-20       Impact factor: 5.840

9.  Coronavirus Disease 2019 Exposure in Surgeons and Anesthesiologists at a New York City Specialty Hospital: A Cross-Sectional Study of Symptoms and SARS-CoV-2 Antibody Status.

Authors:  Ellen M Soffin; Marie-Jacqueline Reisener; Douglas E Padgett; Bryan T Kelly; Andrew A Sama; Jiaqi Zhu; Stephan N Salzmann; Erika Chiapparelli; Ichiro Okano; Lisa Oezel; Andy O Miller; Frank P Cammisa; Federico P Girardi; Alexander P Hughes
Journal:  J Occup Environ Med       Date:  2021-06-01       Impact factor: 2.306

10.  Can We Protect Those We Care for in A Pandemic? - Prevalence of Neutralizing Antibodies against SARS-CoV-2 in Nursing Homes.

Authors:  Harald Willschke; Thomas Wochele-Thoma; Atanas G Atanasov; Elisabeth Klager; Christian Haslinger; Maria Kletecka-Pulker; Daniel Laxar; Care Ay; Thomas Öhlinger; Oliver Kimberger; Adi Steinrigl; Barbara Holzer; Florian Heger; Alexander Indra
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.